Found: 4
Select item for more details and to access through your institution.
Serum C-Reactive Protein at Diagnosis and Response to Therapy Is the Most Powerful Factor Predicting Outcome of Multiple Myeloma Treated with Thalidomide/ Anthracycline–Based Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 5, p. 294
- By:
- Publication type:
- Article
Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 6, p. 423, doi. 10.1016/j.clml.2012.06.008
- By:
- Publication type:
- Article
Thalidomide-dexamethasone versus Interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
- Published in:
- British Journal of Haematology, 2009, v. 144, n. 5, p. 653, doi. 10.1111/j.1365-2141.2008.07495.x
- By:
- Publication type:
- Article
Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA.
- Published in:
- Oncologist, 2012, v. 17, n. 5, p. 663, doi. 10.1634/theoncologist.2011-0355
- By:
- Publication type:
- Article